Medical EmExome: Clinical Exome Sequencing, Additional Family Member

<table>
<thead>
<tr>
<th>Test Code: EXOMA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Turnaround time: 8 weeks</td>
</tr>
<tr>
<td>CPT Codes: 81416 x1</td>
</tr>
</tbody>
</table>

**Condition Description**

Traditionally there are two options when ordering exome sequencing. One can analyze only the affected individual (proband only) or a family trio (typically the affected person and his/her parents). Analyzing trios has shown to increase the diagnostic yield of exome sequencing by provide deeper insight into proband’s findings. Emory Genetics Laboratory (EGL) now offers an additional family member option to further increase the clinical efficacy of its exome sequencing. This test allows clinicians to send in an additional child or family member (affected or unaffected) to help sort out findings of unclear significance.

The sequencing design of the Medical EmExome at EGL provides >97% coverage of 22,000 genes, with a mean read depth of 100X. Of the ~4600 disease-associated genes analyzed, 3000 have 100% coverage (?20X) of all exons; twice the number of genes with complete coverage offered by competitors, making it the most comprehensive exome sequencing test available. This is also the highest coverage offered by any clinical exome sequencing performed in a CLIA-/CAP-certified laboratory.

Please note this test should be ordered at the same time as the “Medical EmExome: Clinical Exome Sequencing, Family Trios” (test code: EXOMT).

The Exome Coverage Tool can be used to view typical depth of sequence coverage obtained by exome sequencing performed by EGL. To access this tool, please click [here](#).

**Indications**

The Medical EmExome is indicated when there is a suspicion of a genetic etiology contributing to the proband’s manifestations.

**Methodology**

Medical EmExome is performed on genomic DNA, using the Agilent V5 Plus designed to target the exome with greater coverage of known disease-associated genes. These targeted regions are then sequenced using the Illumina HiSeq 2500 sequencing system, with 100 basepair (bp) paired-end reads (similar to bidirectional Sanger sequencing) and an average coverage of 100X in the target region. (The target region includes the exon and 10 bp of flanking intronic region). The DNA sequence is mapped to, and analyzed in, comparison with the published human genome build UCSC hg19 reference sequence. The targeted coding exons and splice junctions of the known protein-coding RefSeq genes are assessed for the depth of coverage and data quality threshold values. The Medical EmExome bioinformatics analysis pipeline is used to compare sequence changes in the individual being tested to the reference sequence. All potential positive sequence variants in the proband are confirmed by conventional di-deoxy DNA sequence analysis (Sanger sequencing) using a separate DNA isolation.

**Detection**

Unknown.

**Specimen Requirements**

**Additional Specimen Collection/Handling Instructions Required for this Test**

Whole blood (or DNA extracted from whole blood) is needed from the proband and the additional family member. Please send all samples at the time.

Please contact the lab before submitting any other specimen type.

Submit only 1 of the following specimen types.

**Type: Whole Blood**

Specimen Requirements:

In EDTA (purple top) or ACD (yellow top) tube: 5-10 ml for all ages.

Specimen Collection and Shipping: Refrigerate until time of shipment. Ship sample within 5 days of collection at room temperature with overnight delivery.

**Special Instructions**

Please submit medical records or clinic summary notes, and a signed consent form when ordering exome testing. Testing will not be initiated until these documents are received.
### Related Tests

- Medical EmExome: Clinical Exome Sequencing
- Medical EmExome: Clinical Exome Sequencing, Family Trios
- Medical EmExome Array: Deletion/Duplication Analysis